|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Guha N, Warnakulasuriya S, Vlaanderen J
and Straif K: Betel quid chewing and the risk of oral and
oropharyngeal cancers: A meta-analysis with implications for cancer
control. Int J Cancer. 135:1433–1443. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pednekar MS, Gupta PC, Yeole BB and Hebert
JR: Association of tobacco habits, including bidi smoking, with
overall and site-specific cancer incidence: Results from the Mumbai
cohort study. Cancer Causes Control. 22:859–868. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Radoï L and Luce D: A review of risk
factors for oral cavity cancer: The importance of a standardized
case definition. Community Dent Oral Epidemiol. 41:97–109,
e178-e191. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wikner J, Gröbe A, Pantel K and Riethdorf
S: Squamous cell carcinoma of the oral cavity and circulating
tumour cells. World J Clin Oncol. 5:114–124. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Newman DJ, Cragg GM and Snader KM: Natural
products as sources of new drugs over the period 1981–2002. J Nat
Prod. 66:1022–1037. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brinker AM, Ma J, Lipsky PE and Raskin I:
Medicinal chemistry and pharmacology of genus Tripterygium
(Celastraceae). Phytochemistry. 68:732–766. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gao JM, Wu WJ, Zhang JW and Konishi Y: The
dihydro-beta-agarofuran sesquiterpenoids. Nat Prod Rep.
24:1153–1189. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Salminen A, Lehtonen M, Suuronen T,
Kaarniranta K and Huuskonen J: Terpenoids: Natural inhibitors of
NF-kappaB signaling with anti-inflammatory and anticancer
potential. Cell Mol Life Sci. 65:2979–2999. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tiedemann RE, Schmidt J, Keats JJ, Shi CX,
Zhu YX, Palmer SE, Mao X, Schimmer AD and Stewart AK:
Identification of a potent natural triterpenoid inhibitor of
proteosome chymotrypsin-like activity and NF-kappaB with
antimyeloma activity in vitro and in vivo. Blood. 113:4027–4037.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu CC, Chan ML, Chen WY, Tsai CY, Chang FR
and Wu YC: Pristimerin induces caspase-dependent apoptosis in
MDA-MB-231 cells via direct effects on mitochondria. Mol Cancer
Ther. 4:1277–1285. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guo Y, Zhang W, Yan YY, Ma CG, Wang X,
Wang C and Zhao JL: Triterpenoid pristimerin induced HepG2 cells
apoptosis through ROS-mediated mitochondrial dysfunction. J BUON.
18:477–485. 2013.PubMed/NCBI
|
|
13
|
Deeb D, Gao X, Liu YB, Pindolia K and
Gautam SC: Pristimerin, a quinonemethide triterpenoid, induces
apoptosis in pancreatic cancer cells through the inhibition of
pro-survival Akt/NF-kappaB/mTOR signaling proteins and
anti-apoptotic Bcl-2. Int J Oncol. 44:1707–1715. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu YB, Gao X, Deeb D, Arbab AS and Gautam
SC: Pristimerin induces apoptosis in prostate cancer cells by
down-regulating Bcl-2 through ROS-dependent Ubiquitin-proteasomal
degradation pathway. J Carcinog Mutagen Suppl. 6:0052013.
|
|
15
|
Byun JY, Kim MJ, Eum DY, Yoon CH, Seo WD,
Park KH, Hyun JW, Lee YS, Lee JS, Yoon MY and Lee SJ: Reactive
oxygen species-dependent activation of Bax and poly(ADP-ribose)
polymerase-1 is required for mitochondrial cell death induced by
triterpenoid pristimerin in human cervical cancer cells. Mol
Pharmacol. 76:734–744. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu Z, Jin Y, Chen C, Li J, Cao Q and Pan
J: Pristimerin induces apoptosis in imatinib-resistant chronic
myelogenous leukemia cells harboring T315I mutation by blocking
NF-kappaB signaling and depleting Bcr-Abl. Mol Cancer. 9:1122010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Call JA, Eckhardt SG and Camidge DR:
Targeted manipulation of apoptosis in cancer treatment. Lancet.
Oncol. 9:1002–1011. 2008.
|
|
19
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Molinari M: Cell cycle checkpoints and
their inactivation in human cancer. Cell Prolif. 33:261–274. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nakanishi M, Shimada M and Niida H:
Genetic instability in cancer cells by impaired cell cycle
checkpoints. Cancer Sci. 97:984–989. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ball KL: p21: Structure and functions
associated with cyclin-CDK binding. Prog Cell Cycle Res. 3:125–134.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Castedo M, Perfettini JL, Roumier T and
Kroemer G: Cyclin-dependent kinase-1: Linking apoptosis to cell
cycle and mitotic catastrophe. Cell Death Differ. 9:1287–1293.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guo H, Ray RM and Johnson LR: RhoA
stimulates IEC-6 cell proliferation by increasing
polyamine-dependent Cdk2 activity. Am J Physiol Gastrointest Liver
Physiol. 285:G704–G713. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sherr CJ and Roberts JM: Living with or
without cyclins and cyclin-dependent kinases. Genes Dev.
18:2699–2711. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee JS, Yoon IS, Lee MS, Cha EY, Thuong
PT, Diep TT and Kim JR: Anticancer activity of pristimerin in
epidermal growth factor receptor 2-positive SKBR3 human breast
cancer cells. Biol Pharm Bull. 36:316–325. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yousef BA, Guerram M, Hassan HM, Hamdi AM,
Zhang LY and Jiang ZZ: Pristimerin demonstrates anticancer
potential in colorectal cancer cells by inducing G1 phase arrest
and apoptosis and suppressing various pro-survival signaling
proteins. Oncol Rep. 35:1091–1100. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang WH, Hsuan KY, Chu LY, Lee CY, Tyan
YC, Chen ZS and Tsai WC: Anticancer effects of Salvia miltiorrhiza
alcohol extract on oral squamous carcinoma cells. Evid Based
Complement Alternat Med. 2017:53640102017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yan YY, Bai JP, Xie Y, Yu JZ and Ma CG:
The triterpenoid pristimerin induces U87 glioma cell apoptosis
through reactive oxygen species-mediated mitochondrial dysfunction.
Oncol Lett. 5:242–248. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Eum DY, Byun JY, Yoon CH, Seo WD, Park KH,
Lee JH, Chung HY, An S, Suh Y, Kim MJ and Lee SJ: Triterpenoid
pristimerin synergizes with taxol to induce cervical cancer cell
death through reactive oxygen species-mediated mitochondrial
dysfunction. Anticancer Drugs. 22:763–773. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Y, Zhou Y, Zhou H, Jia G, Liu J, Han
B, Cheng Z, Jiang H, Pan S and Sun B: Pristimerin causes G1 arrest,
induces apoptosis, and enhances the chemosensitivity to gemcitabine
in pancreatic cancer cells. PLoS One. 7:e438262012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ba XH, Cai LP and Han W: Effect of
cilostazol pretreatment on the PARP/AIF-mediated apoptotic pathway
in rat cerebral ischemia-reperfusion models. Exp Ther Med.
7:1209–1214. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wan Y, Xin Y, Zhang C, Wu D, Ding D, Tang
L, Owusu L, Bai J and Li W: Fermentation supernatants of
Lactobacillus delbrueckii inhibit growth of human colon cancer
cells and induce apoptosis through a caspase 3-dependent pathway.
Oncol Lett. 7:1738–1742. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cantrell DA: Phosphoinositide 3-kinase
signalling pathways. J Cell Sci. 114:1439–1445. 2001.PubMed/NCBI
|
|
35
|
Liu Z, Zhu G, Getzenberg RH and Veltri RW:
The upregulation of PI3K/Akt and MAP kinase pathways is associated
with resistance of microtubule-targeting drugs in prostate cancer.
J Cell Biochem. 116:1341–1349. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xie G, Yu X, Liang H, Chen J, Tang X, Wu S
and Liao C: Pristimerin overcomes adriamycin resistance in breast
cancer cells through suppressing Akt signaling. Oncol Lett.
11:3111–3116. 2016. View Article : Google Scholar : PubMed/NCBI
|
